PARP抑制剂联合抗血管生成药物治疗晚期上皮性卵巢癌的依据综述
本综述梳理了PARP抑制剂与抗血管生成药物单药及联合方案在晚期卵巢癌中的研究证据,纳入PARP抑制剂研究8项、抗血管生成研究4项、联合研究7项,涵盖初诊7项与复发12项。联合方案在复发场景基于客观缓解率和PFS显示疗效,奥拉帕利联合抗血管生成维持治疗在同源重组缺陷阳性初诊患者中较抗血管生成单药显著改善PFS,且耐受性可接受、未见新安全性信号。
要点
- PARP抑制剂联合抗血管生成在复发卵巢癌中基于ORR和PFS显示疗效。
- 奥拉帕利联合抗血管生成维持治疗在HRD阳性初诊患者中PFS获益显著。
- 联合治疗耐受性与单药研究相当,未报告新的安全性信号。
核心结论
- PARP抑制剂联合抗血管生成药物是晚期卵巢癌有前景的新型治疗选择,但联合方案在复发疾病中的角色仍需进一步阐明。
研究设计与样本
- 本综述纳入PARP抑制剂单药研究8项、抗血管生成单药研究4项、联合治疗研究7项,涵盖初诊卵巢癌7项与复发卵巢癌12项。
- 纳入的PARP抑制剂包括奥拉帕利9项、尼拉帕利4项、芦卡帕利1项、维利帕利1项;抗血管生成药物包括贝伐珠单抗7项、西地尼布4项。
主要发现
- PARP抑制剂联合抗血管生成药物在复发疾病场景中基于客观缓解率和无进展生存期显示疗效。
- 奥拉帕利联合抗血管生成维持治疗在初诊晚期卵巢癌且同源重组缺陷检测阳性的女性中,较抗血管生成单药显著改善无进展生存期。
- 联合治疗可耐受,与单药研究相比未报告新的安全性信号。
临床怎么用
- PARP抑制剂联合抗血管生成方案可作为初诊晚期和复发卵巢癌的新型治疗选择。
- 需结合单药与联合方案各自的安全性特征,界定哪些患者适合单药或联合治疗。
- 需考虑这些治疗在临床实践中的排序方式。
局限性
- 联合方案在复发疾病中的作用仍需进一步阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inhibitors of poly(ADP-ribose) polymerase (PARP) and angiogenesis have demonstrated single-agent activity in women with advanced ovarian cancer. Recent studies have aimed to establish whether combination therapy can augment the response seen with PARP inhibitors or antiangiogenic agents alone. This review provides an overview of PARP inhibitors and antiangiogenics as monotherapy in women with advanced ovarian cancer, explores potential mechanisms of action of PARP inhibitor and antiangiogenic combination treatments, reviews efficacy and safety data from trials evaluating this combination, and outlines ongoing and future trials evaluating this combination, discussing these in the context of the current and future treatment landscape for women with advanced ovarian cancer. Sentinel studies evaluating PARP inhibitor (n = 8), antiangiogenic (n = 4), and combination (n = 7) therapy were identified in women with newly diagnosed (n = 7) and recurrent (n = 12) ovarian cancer. PARP inhibitors included olaparib (n = 9), niraparib (n = 4), rucaparib (n = 1), and veliparib (n = 1). Antiangiogenic agents included bevacizumab (n = 7) and cediranib (n = 4). PARP inhibitors combined with antiangiogenics demonstrated efficacy based on objective response rates and progression-free survival (PFS) in the relapsed disease setting. Maintenance therapy with the PARP inhibitor, olaparib, plus antiangiogenic therapy offered a significant PFS benefit versus the antiangiogenic alone in women with newly diagnosed advanced ovarian cancer who tested positive for homologous recombination deficiency. Combination therapy was tolerated, with no new safety signals reported compared with monotherapy trials. PARP inhibitors and antiangiogenics have changed the landscape of ovarian cancer treatment. The PARP inhibitor plus antiangiogenic combination is a novel treatment option that appears promising in the first-line advanced and recurrent ovarian cancer settings, although the role of this combination in recurrent disease requires further elucidation. Defining which patients are candidates for monotherapy or combination therapy is critical, taking into consideration safety profiles of therapies alone or in combination, and how these treatments should be sequenced in clinical practice.
引用
- Alvarez Secord A, O'Malley DM, Sood AK, et al. Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review. Gynecol Oncol. 2021. PMID: 34090705. doi:10.1016/j.ygyno.2021.05.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。